healthline.com

Once the genes are in place, the yeast or bacteria then start to produce building blocks of human collagen. The ability to make inexpensive, safe collagen sourced from microbes instead of animals has many promising applications for human health. While it hasn’t rolled out as a mass-produced product yet, this has potential to lower the cost of collagen for all consumers and make it widely available for various uses from medical treatments to supplements. The majority of collagen supplements on the market are animal-based, which means people who live an environmentally-friendly or vegan-friendly lifestyle can’t access these products.

Based on Moderna’s and Pfizer’s clinical trials, which both started at the end of July, experts have been able to show that the vaccines have long-lasting protection, but the actual length of time is still unknown. Based on current projections, healthy people under the age of 65 with no medical conditions that put them at higher risk for COVID-19 complications, and who are not in one of the other priority categories (healthcare worker, essential worker, first responder) can probably expect to start getting their vaccinations by early spring, late March through April,” Dr. Aadia Rana, associate professor of medicine in the University of Alabama-Birmingham’s Division of Infectious Diseases, told Healthline, Vaccine manufacturers are working quickly to produce and ship it quickly. ’s safety in pregnant women,” Bernstein said, “I believe pregnant women should know that the mRNA vaccine is not a live vaccine and it is degraded quickly by a normal cellular process. Among the participants of phase 2 and phase 3 clinical trials, several people have subsequently become pregnant and, according to ACOG, these people are being followed to collect safety outcomes.

An advisory group recommended the Food and Drug Administration (FDA) issue an emergency use authorization (EUA) for Moderna’s coronavirus vaccine for people 18 years and older. The vote on Thursday, Dec. 17, came after the panel of independent scientific experts, infectious disease doctors, and statisticians spent much of the day reviewing from Moderna’s phase 3 clinical trial. Overall, the data show that the vaccine is extremely effective — 94.1 percent — at preventing symptomatic COVID-19 cases and 100 percent effective at preventing severe COVID-19 cases,” said Dr. Shobha Swaminathan, an associate professor and infectious disease physician at Rutgers New Jersey Medical School. U. S. officials said they plan to ship just under 6 million doses of Moderna’s vaccine to the states as soon as the FDA issues the EUA.

Those who’ve gotten the shot say it’s a quick, painless process that will increase community-level immunity and decrease healthcare workers’ risks of contracting the new coronavirus on the job. ” Ogbuagu said these initial vaccinations will boost the number of people who are less vulnerable to COVID-19, allow healthcare workers to safely do their jobs, and contribute to immunity levels within the community. Therefore, even with a vaccine now available to healthcare workers, it’s going to be a rough couple of months as hundreds of thousands of people in the United States are currently developing COVID-19 every week. The first priority group includes people who come into close contact with people with COVID-19: emergency medicine physicians, intensive care unit (ICU) doctors, and healthcare workers within COVID-19 units.